ClearPoint Neuro (CLPT) Projected to Release Earnings on Wednesday

ClearPoint Neuro (NASDAQ:CLPT) is expected to be issuing its Q3 2026 results after the market closes on Wednesday, October 28th. Analysts expect the company to announce earnings of ($0.27) per share and revenue of $12.30 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, October 28, 2026 at 4:30 PM ET.

ClearPoint Neuro (NASDAQ:CLPT) last released its quarterly earnings results on Monday, August 3rd. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.09). ClearPoint Neuro had a negative return on equity of 188.09% and a negative net margin of 81.76%. The firm had revenue of $10.88 million for the quarter, compared to analysts’ expectations of $12.73 million. During the same quarter in the prior year, the business earned ($0.21) earnings per share. On average, analysts expect ClearPoint Neuro to post ($1.22) EPS for the current fiscal year and ($1.16) EPS for the next fiscal year.

ClearPoint Neuro Trading Up 3.1%

Shares of NASDAQ CLPT opened at $9.45 on Wednesday. ClearPoint Neuro has a twelve month low of $8.27 and a twelve month high of $27.27. The company has a current ratio of 4.74, a quick ratio of 3.89 and a debt-to-equity ratio of 4.66. The stock has a fifty day simple moving average of $13.37 and a 200-day simple moving average of $13.51. The stock has a market capitalization of $288.23 million, a PE ratio of -8.01 and a beta of 1.29.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of ClearPoint Neuro in a research report on Thursday, October 15th. Stifel Nicolaus set a $22.00 price objective on ClearPoint Neuro in a research report on Tuesday, August 4th. Lake Street Capital set a $25.00 target price on shares of ClearPoint Neuro in a research report on Tuesday, August 4th. Finally, Wall Street Zen downgraded ClearPoint Neuro from a “sell” rating to a “strong sell” rating in a report on Saturday, August 8th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, ClearPoint Neuro presently has a consensus rating of “Hold” and an average price target of $25.67.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc is a medical technology company that develops and commercializes image-guided systems for minimally invasive neurosurgical procedures. Its platform is designed to help physicians plan, navigate and monitor procedures within the brain, using magnetic resonance imaging (MRI) to support accurate placement of instruments and therapeutic agents.

The company’s product portfolio includes the ClearPoint Neuro navigation system and related disposable components, including cranial access and guidance products.